Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse

TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 ...
Targeted Oncology

Phase I Trial of Neoantigen Vaccine Shows 100% DFS Rate in HNSCC

Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...
Morningstar

Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025

Intra-tumoral BT-001 injection in combination with IV pembrolizumab was well tolerated with a manageable safety profile. Tumor shrinkage was observed in both injected and non-injected lesions. BT-001 ...
finanzen.at

Transgene's TG4050 Shows 100% Two-Year Disease-Free Survival In Phase I Head & Neck Cancer Trial

Transgene (TRGNF, TNG.PA), a biotechnology company developing virus-based immunotherapies for cancer, announced the preprint ...